Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

被引：0
|
作者：
Mostaghel, Elahe A.
Wang, Xin Victoria
Marck, Brett
Matsumoto, Alvin M.
Sweeney, Christopher
机构：
[1] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy
    Neuberger, Manuel
    Skladny, Janina
    Goly, Nora
    Wessels, Frederik
    Weiss, Christel
    Egen, Luisa
    Erben, Philipp
    Gross-Weege, Matthias
    Gruene, Britta
    Hartung, Friedrich
    Herrmann, Jonas
    Honeck, Patrick
    Jarczyk, Jonas
    Kowalewski, Karl-Friedrich
    Muehlbauer, Julia
    Nitschke, Katja
    Nientiedt, Malin
    Walach, Margarete Theresa
    Waldbillig, Frank
    Westhoff, Niklas
    Von Hardenberg, Jost
    Kriegmair, Maximilian
    Worst, Thomas S.
    Nuhn, Philipp
    ANTICANCER RESEARCH, 2022, 42 (04) : 1911 - 1918
  • [42] SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Lobbedez, F. Joly
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Krakowski, I.
    Laguerre, B.
    Rolland, F.
    Theodore, C.
    Deplanque, G.
    Ferrero, J. M.
    Pouessel, D.
    Mourey, L.
    Beuzeboc, P.
    Zanetta, S.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 294 - 294
  • [43] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
    Petrylak, D. P.
    Azad, A. A.
    Szmulewitz, R. Z.
    Iguchi, T.
    Shore, N. D.
    Holzbeierlein, J.
    Alekseev, B.
    El-Chaar, N. N.
    Rosbrook, B.
    Ma, J.
    Zohren, F.
    Haas, G. P.
    Stenzl, A.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1183 - S1184
  • [44] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
    Alcaraz, A.
    Szmulewitz, R. Z.
    Shore, N.
    Crawford, E. D.
    Petrylak, D. P.
    Holzbeierlein, J.
    Villers, A.
    Azad, A. A.
    Alekseev, B.
    Iguchi, T.
    Gomez-Veiga, F.
    Rosbrook, B.
    Sugg, J.
    Haas, G. P.
    Stenzl, A.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S523 - S524
  • [45] The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.
    Hawley, Jessica E.
    Dallos, Matthew
    Lim, Emerson A.
    Runcie, Karie
    Hu, Jianhua
    Lowy, Israel
    Drake, Charles G.
    Stein, Mark N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT plus Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry
    Francini, E.
    Yip, S.
    Ahmed, N. S.
    Li, H.
    Ardolino, L.
    Evan, C. P.
    Kaymakcalan, M.
    Shaw, G. K.
    Kantoff, P.
    Taplin, M. E.
    Alimohamed, N.
    Joshua, A. M.
    Heng, D. Y. C.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.
    Francini, Edoardo
    Gray, Kathryn P.
    Evan, Carolyn
    Kaymakcalan, Marina D.
    Shaw, Grace Katherine
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
    Saad, F.
    Hussain, M.
    Tombal, B.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Boegemann, M.
    Tutrone, R.
    Littleton, N.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S964 - S964
  • [49] Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216)
    Parikh, Mamta
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Jo, Yeonjung
    Harzstark, Andrea
    Paller, Channing Judith
    George, Saby
    Zibelman, Matthew R.
    Cheng, Heather H.
    Maughan, Benjamin L.
    Zhang, Jingsong
    Pachynski, Russell Kent
    Bryce, Alan Haruo
    Lin, Daniel W.
    Quinn, David I.
    Thompson, Ian M.
    Dorff, Tanya B.
    Lara, Primo N.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study
    Lopez-Abad, Alicia
    Belmonte, Mario
    Backhaus, Miguel Ramirez
    Gomez, Gerardo Server
    Avellaneda, Enrique Cao
    Alarcon, Cristobal Moreno
    Cubillana, Pedro Lopez
    Gimenez, Pablo Yago
    Rodriguez, Pedro de Pablos
    Fita, Maria Jose Juan
    Duran, Miguel angel Climent
    Ruiz, Iris Guardiola
    Crespo, Natalia Vidal
    Aviles, Juan Moreno
    Martinez-Valls, Pablo Luis Guzman
    Gonzalez, Pedro angel Lopez
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
12345